OMB #: 0925-0476 									                     Exp. Date: 07/31/2009			

Survey Questions for Principal Investigators of Other Screening/Probe Production Centers

Public reporting burden for this collection of information is estimated to average 7 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0476). Do not return the completed form to this address. 

A.	Network Customer Satisfaction: How well is the network serving the needs of the community?
1.	What aspects of the MLPCN network are unique?
a)	Do other centers deposit their data in free access databases?
b)	If there are other databases, are the compounds the same?
c)	Do other screening centers screen annotated compound sets?
d)	Do other centers provide access to medicinal chemistry?
e)	How many assays per year do other centers receive/screen against how many compounds?
f)	How were the compounds in the library selected?
g)	How do other centers store & distribute their library contents?

B.	Probes & Probe Reports: What is the usefulness of the probes produced?
1.	Do the probes produced reflect the state of the art in probe development/production?
a)	What is the current or potential application of MLSCN/MLPCN data and probes to your research? 
b)	What is the current or potential application of MLSCN/MLPCN data and probes to the broader research community? 

C.	Sustainability of the Network: What is the best model for the future of the MLPCN?
1.	In 2014, the MLPCN will transition from the 10-year start-up funding providing by the NIH Roadmap. What are the business models for other large service or resource programs that would be a good fit for sustaining the MLPCN after Roadmap funding ends?